Illinois Municipal Retirement Fund Purchases 4,528 Shares of Glaukos Corporation $GKOS
by Michael Walen · The Markets DailyIllinois Municipal Retirement Fund raised its position in Glaukos Corporation (NYSE:GKOS – Free Report) by 17.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 30,142 shares of the medical instruments supplier’s stock after purchasing an additional 4,528 shares during the period. Illinois Municipal Retirement Fund’s holdings in Glaukos were worth $4,949,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of the company. Quantinno Capital Management LP raised its position in shares of Glaukos by 964.0% in the 1st quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock worth $3,320,000 after acquiring an additional 27,938 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Glaukos in the 2nd quarter valued at about $20,293,000. BlackRock Inc. acquired a new position in shares of Glaukos in the 2nd quarter valued at about $1,333,318,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Glaukos during the 2nd quarter valued at about $3,361,000. Finally, Wellington Management Group LLP boosted its position in shares of Glaukos by 187.1% during the 2nd quarter. Wellington Management Group LLP now owns 428,215 shares of the medical instruments supplier’s stock valued at $59,847,000 after purchasing an additional 279,065 shares in the last quarter. 99.04% of the stock is owned by institutional investors.
Insider Activity at Glaukos
In other news, Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director owned 37,406 shares in the company, valued at $9,463,718. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.
Glaukos Stock Performance
Shares of GKOS opened at $245.60 on Monday. Glaukos Corporation has a one year low of $87.32 and a one year high of $255.18. The company has a market cap of $14.54 billion, a PE ratio of -83.54 and a beta of 0.68. The stock has a 50-day moving average of $184.61 and a 200-day moving average of $147.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09.
Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The firm’s revenue for the quarter was up 58.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.16) EPS. On average, equities research analysts predict that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently commented on GKOS. Truist Financial raised their target price on Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. Piper Sandler restated an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a report on Thursday, October 29th. Stifel Nicolaus raised their price objective on shares of Glaukos from $190.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $200.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $216.71.
Read Our Latest Analysis on GKOS
About Glaukos
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Featured Articles
- Five stocks we like better than Glaukos
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).